-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Kura Oncology announced today that its investigational therapy tipifarnib has received a breakthrough therapy designation granted by the U.
HNSCC is the seventh most common cancer in the world, with more than 885,000 new cases each year.
HRAS gene mutation mediates tumor proliferation and drug resistance in many solid tumors, and is an important target in the field of anti-cancer drug development.
This breakthrough therapy designation is based on data from a phase 2 clinical trial called RUN-HN.
"We are very pleased that the FDA has granted tipifarnib a breakthrough therapy designation, which is an affirmation of its therapeutic potential.